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Abstract
Insulin-like growth factor (IGF) binding protein-1
(IGFBP-1) is generally believed to inhibit IGF action in
the circulation. In contrast, IGFBP-1 has been reported to
interact with cell surfaces and enhance IGF-I action locally
in some tissues. Renal IGFBP-1 levels are found elevated
in various conditions characterized by renal growth (e.g.
diabetes mellitus, hypokalemia).
To test whether IGFBP-1 is a renotropic factor,
IGFBP-1 was administered alone or in combination with
IGF-I to Snell dwarf mice, an in vivo model without
compensatory feedback effects on growth hormone (GH)
secretion. In three control groups of Snell dwarf mice,
placebo, GH or IGF-I was administered. Compared with
placebo, kidney weight increased in all treated groups,
however, with different effects on kidney morphology.
Administration of IGF-I, alone or in combination with
IGFBP-1, tended to increase glomerular volume, while no
changes were seen in the other groups. Administration
of IGFBP-1 or IGFBP-1+IGF-I both caused dilatation
of the thin limbs of Henle’s loop, while GH or IGF-I
administration had no visible effect. Furthermore,
IGF-I administration resulted in an increased mean
number of nuclei per cortical area and renal weight,
whereas GH, IGF-I+IGFBP-1 or IGFBP-1 caused a
decreased renal nuclei number.
In situ hybridization and immunohistochemistry showed
specific changes of the renal IGF system expression
patterns in the different groups. Particularly, IGFBP-1
administration resulted in extensive changes in the
mRNA expression of the renal IGF system, whereas the
other administration regimen resulted in less prominent
modifications. In contrast, administration of IGFBP-1 and
IGFBP-1+IGF-I resulted in identical changes in the
protein expression of the renal IGF system.
Our results indicate that IGFBP-1, alone or in combi-
nation with IGF-I, demonstrated effects on the renal
tubular system that differ from the effects of IGF-I.
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Introduction
The growth promoting effects of the growth hormone
(GH)–insulin-like growth factor (IGF) axis on body and
organ growth seem to be highly dependent on the
distribution of the IGF binding proteins (IGFBPs).
IGFBP-1, generally believed to inhibit IGF action in the
circulation, has also been reported to interact with
cell surfaces and enhance local IGF-I action (Jones &
Clemmons 1995, Lee et al. 1997). In various conditions
characterized by renal growth, renal IGFBP-1 levels have
been reported to be elevated (e.g. diabetes mellitus,
hypokalemia) (Flyvbjerg 1993, Hsu et al. 1997, van Neck
et al. 1997).
In man, circulating levels of IGFBP-1 are raised at short
term in diabetes (Flyvbjerg 1993, Fervenza et al. 1997). In
experimental diabetes in rodents, serum levels of IGFBP-1
are elevated as well, together with decreased IGF-I levels
(Luo & Murphy 1992, Bach et al. 1994). In contrast, renal
IGF-I concentrations are elevated despite an unchanged
local production (Flyvbjerg et al. 1990, Landau et al. 1995,
Raz et al. 1998). However, in the renal cortex of diabetic
rodents, IGFBP-1 mRNA is strongly increased (Landau
et al. 1995). Taken together, it is tempting to speculate
that renal IGF-I is increased due to entrapment by
IGFBP-1.
Potassium depletion also is characterized by a selective
renal growth (Gustafson et al. 1973, Flyvbjerg et al. 1991).
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In the hypertrophic kidneys of these animals, increased
amounts of IGFBP-1 mRNA and protein were observed
(Hsu et al. 1997, Rohan et al. 1997). This increase in renal
IGFBP-1 mRNA expression in potassium-deficient rats
was not affected by IGF-I infusion (van Neck et al. 1997).
In order to test the renotropic effects of IGFBP-1 in an
in vivo model, without compensatory feedback effects
on GH secretion, IGFBP-1 was administered, alone or
in combination with IGF-I, to Pit-1 deficient Snell
dwarf mice. We have demonstrated that treatment of
homozygous Snell dwarf mice with GH and IGF-I, for a
period of 4 weeks, caused an increase in body length and
body weight, whereas IGFBP-1 administration had no
effect (van Buul-Offers et al. 2000). Furthermore, GH,
IGF-I and IGFBP-1 treatment also had a pronounced
effect on kidney size. Although IGFBP-1 inhibited IGF-I
induced total body growth, it further stimulated IGF-I
induced kidney growth (van Buul-Offers et al. 2000).
The aim of the present study was to investigate in
further detail the renotropic effects of IGFBP-1, alone or
in combination with IGF-I. In three control groups of
Snell dwarf mice, placebo, GH or IGF-I was administered.
We analyzed the effects of the different administrations on
kidney morphology and kidney-specific mRNA and pro-
tein expression of the different members of the IGF
system.
Materials and Methods
Test substances
E. coli-derived recombinant human IGF-I was kindly
provided by Eli Lilly Co. (Indianapolis, IN, USA). Re-
combinant human GH was from Amersham-Pharmacia
(Uppsala, Sweden). Human IGFBP-1 was purified as
described previously (van Buul-Offers et al. 2000) from
amniotic fluid from pregnant women (midterm) which
was obtained for diagnostic purposes and approved by the
institutional Ethics committee.
Animal experimentation
The experimental design has been described in detail
previously (van Buul-Offers et al. 2000). Briefly, in two
independent long-term experiments, groups of Snell
dwarf mice (males and females, aged 6–8 weeks and
with identical mean lengths and weights at the start of
the experiments) received GH (8·3 µg/day), IGF-I
(30 µg/day), IGFBP-1 (105 µg/day), IGF-I+IGFBP-1
(30+105 µg/day) or PBS (control) for 4 weeks. In order to
avoid hypoglycemia, 10% glucose was added to the
drinking water, starting 1 week before the experiment.
The dwarf mice (n=5 per group in each experiment) were
injected s.c. in the neck with 0·1 ml hormone solution or
vehicle, three times daily, 5 days a week. In this article we
discuss the findings of the first experiment. However, the
second experiment resulted in comparable findings. The
study complied with Dutch regulations for care and use of
laboratory animals.
Tissue isolation
Animals were killed 2 h after the last injection. Kidneys
were removed and weighed to the nearest milligram, fixed
overnight in 4% paraformaldehyde, and embedded in
paraffin. Sections (4 µm) were cut and mounted on
aminopropyl trioxysilane-coated slides. Slides were dried
at 37 C for 3 days. In order to obtain optimal comparison
between the different treatments, all organs were fixed,
embedded in paraffin, and mounted on slides similarly and
at the same time. Kidney sections of all groups have been
mounted on the same slide. As a result, the experimental
parameters of in situ hybridization and immunohisto-
chemistry experiments per probe or antibody, respectively,
were the same for all administration groups.
Morphology
To determine kidney size, the central sections from series
of sagittal sections of kidneys were measured with a ruler.
To count the number of nuclei per square, sections were
placed under a light microscope with a grid. Per section 3
cortical areas were counted (=nuclei in a total area of
0·25 mm2) of five animals per treatment group (=75
counts in total).
Cell proliferation
Human proliferating cell nuclear antigen (PCNA) was
detected using anti-human PCNA (Roche Diagnostics,
Almere, The Netherlands) in a dilution of 1:1000 and
detected using the Vectastain peroxidase-conjugated elite
ABC kit (Vector Laboratories, Burlingame, CA, USA).
Cell proliferation was estimated by determining the
number of PCNA positive nuclei in central sections from
series of sagittal sections of kidneys under a light micro-
scope with a grid. Three sections were counted per animal
of three animals per treatment group.
Probe preparation ( in situ hybridization)
Specific mouse IGFBP cRNA probes were transcribed
from IGFBP-2, -3, -4, -5, -6 cDNAs as described by
Schuller et al. (1994). The mouse cDNA Sph1-Sac1
fragment was used as template for the IGFBP-1 cRNA
probe and was cloned into pTZ18R or pTZ19R
(Pharmacia, Uppsala, Sweden) for the antisense and
sense probes respectively. Similarly, mouse IGF-I and -II
cDNAs (kindly provided by Dr G. I. Bell, Howard
Hughes Institute, Chicago, IL, USA) fragments were
subcloned into pTZ18 and pTZ19 (EcoRI for IGF-I and
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BamHI/Sac1 for IGF-II). A 265 bp EcoRI/Sma1 frag-
ment of the rat type I IGF receptor cDNA ligated in
PGEM3 (Promega, Madison, WI, USA) was kindly pro-
vided by Dr H. Werner and Dr D. LeRoith (National
Institutes of Health, Bethesda, MD, USA) and was used as
template for the type I IGF receptor probe. Digoxigenin-
11-UTP labeled RNA probes were prepared according to
the manufacturer’s prescription (Boehringer Mannheim
GmbH, Biochemica, Mannheim, Germany), using T7 or
SP6 RNA polymerase.
In situ hybridization
A non-radioactive in situ hybridization was performed, as
described previously (Lindenbergh-Kortleve et al. 1997).
In short, kidney sections from control and the four
administration groups were mounted on the same glass
slide and processed batch-wise. Hybridization was per-
formed overnight at 55 C in a humid chamber in a
hybridization solution containing 50% deionized forma-
mide, 10% dextran sulfate, 2SSC, 1Denhardt’s
solution, 1 µg/ml tRNA, 250 µg/ml herring sperm DNA
and the respective probes at a concentration of 100 ng/ml.
After various washes (50% formamide/2SSC, 50%
formamide/1SSC and 0·1SSC) sections were incu-
bated with RNase T1 (2 U/ml in 1 mM EDTA/2SSC)
for 15 min at 37 C. The digoxigenin-labeled hybrids
were detected by antibody incubation performed accord-
ing to the manufacturer’s recommendations (Boehringer
Mannheim GmbH, Biochemica, Mannheim, Germany).
PVA (polyvinylalcohol, MW 31–50 kDa, Aldrich
Chemical Co. Milwaukee, WI, USA) enhanced staining
with BCIP (5-bromo-4-chloro-3-indolyl phosphate),
NBT (4-nitroblue tetrazolium chloride) and levamisol was
stopped when the desired intensity of the blue precipitate
was reached. This was dependent on the relative abun-
dance of the respective mRNAs. Sections were counter-
stained with Nuclear red solution and mounted with
Euparal (Chroma Gesellschaft, Stuttgart, Germany). Con-
trol sections for morphological analysis were either stained
with PAS, or with hematoxylin and eosin. In situ hybrid-
ized sections were analyzed blindly by two independent
investigators, in at least five separate observations. Nega-
tive controls for in situ hybridization were performed using
sense probes, which never gave any significant staining.
Immunohistochemistry
Polyclonal antisera to mIGFBP-1, -2, -3, -4, -5 and -6
were used that were previously described (van Kleffens
et al. 1999). Briefly, synthetic peptides (ID-DLO,
Lelystad, the Netherlands), corresponding to parts of the
variable region of the various mouse IGFBPs (IGFBP-1
and IGFBP-2: amino acid position (aa)174–189;
IGFBP-3: aa200–213; IGFBP-4: aa155–170; IGFBP-5:
aa176–191; IGFBP-6: aa128–143), were coupled to the
carrier keyhole limpet hemocyanin (KLH; Pierce,
Rockford, IL, USA) and injected into rabbits. The result-
ing antisera were used in an immunohistochemical stain-
ing, making use of the peroxidase–anti-peroxidase (PAP)
method. Specificity of the antisera was determined using
ELISA, Western blotting and by verifying the staining
patterns in normal versus gene-deletion mutant mice of
the respective protein (van Kleffens et al. 1999). The anti
mIGFBP-1 and -3 polyclonal antisera were diluted 1:150,
while the anti mIGFBP-2, -4, -5 and -6 polyclonal
antisera were used in a dilution of 1:250. Staining patterns
were analyzed in comparison to their respective pre-
immune sera, diluted 1:10. Unlabeled goat anti-rabbit
immunoglobulins (Dako, Glostrup, Denmark; 1:50) were
used as second antibody and rabbit PAP (Dako; 1:100) as
a linker. Rabbit polyclonal antisera against type I IGF-
receptor and goat polyclonal antisera against IGF-I and
IGF-II (all with cross-reactivity to human, mouse and rat,
according to the manufacturer) were obtained from Re-
search Diagnostics Inc. (Flanders, NJ, USA) and used at a
dilution of 1:200. The specificity of the type I IGF-
receptor antibody was assured by blocking the antibody–
receptor binding using a control peptide for competition
consisting of amino acids 31–50 of the human type I
IGF-receptor as obtained from Research Diagnostics Inc.
(Flanders). Staining was performed with diaminobenzidine
(DAB; Fluka Chemika, Buchs, Switzerland; 0·75 mg/ml).
Nuclei were made visible with Mayer’s hematoxylin.
Sections from control and all administration groups were
mounted on the same glass slide and processed batch-wise.
Estimation of glomerular volume
A 2 mm thick horizontally cut slice from the middle of the
kidney (containing the papilla) was fixed in 4% parafor-
maldehyde and embedded in Technovit. Then, 2 µm
thick sections were cut on a rotation microtome and
stained with p-aminosilacylic acid and hematoxylin. Mean
glomerular tuft volume (VG) was determined from the
mean glomerular cross-sectional area (AG) by light
microscopy as previously described (Flyvbjerg et al. 1999).
Profile areas were traced using a computer-assisted mor-
phometric unit (Image Tool: University of Texas Health
Science Center, San Antonio, TX, USA). AG was deter-
mined as the average area of a total of 40–80 glom-
eruli (tuft omitting the proximal tubular tissue within
Bowman’s capsule) and VG was calculated as
VG=/(AG)
3/2, where =1·38, which is the shape
coefficient for spheres (the idealized shape of glomeruli),
and =1·1, which is a size distribution coefficient
(Flyvbjerg et al. 1999).
Statistical analysis
The differences in kidney weight and glomerular volume
after the different administration regimen were analyzed
and expressed as mean... For comparison of multiple
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groups we used ANOVA as described by Scheffé (1959).
Student’s t-test was applied for testing differences between
two groups. A P value equal or less than 0·05 was regarded
as significant.
Results
Kidney weight
Figure 1A shows the weights of the kidneys after 4 weeks
of treatment, expressed as a percentage of the kidney
weight of control animals. All treatment regimen signifi-
cantly increased renal weight. The remarkable effects on
the kidneys obtained with IGFBP-1 alone were signifi-
cantly higher than with IGF-I alone (P0·05), whereas
the combination of IGFBP-1 and IGF-I seemed to
demonstrate an additive effect on renal weight increase.
Renal morphology
To investigate possible differences in renal morphology
between untreated, phenotypically normal heterozygous
Figure 1 (A) Mean kidney weight (per pair of kidneys and expressed as percentage of the
renal weight of control animals) and (B) mean glomerular volume (104 m3) of Snell dwarf
mice injected for 28 days with (from the left) placebo; GH, 8·3 g/day; IGFBP-1,
105 g/day; IGF-I, 30 g/day; and IGF-I+IGFBP-1, 30+105 g/day. Values are
meansS.E.M.s (n=5). Differences between groups were determined by Scheffé’s
(**P0·05) or Student’s t-test (*P0·05; #P0·12).
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(+/dw) and untreated homozygous Snell dwarf mice,
PAS stained sections were examined. No differences in
morphology could be detected. Although kidneys of
homozygous Snell dwarf mice were smaller, they were
proportional to their decreased body size (results not
shown). To examine the effects of the different
administration regimen on the glomeruli, the glomerular
volume was measured in all groups. Compared with pla-
cebo control kidneys, glomerular volume did not change
significantly, although a tendency to increase could be
observed in both the IGF-I and IGFBP-1/IGF-I groups
(P=0·12 and P=0·11 respectively) (Fig. 1B). Figure 2A–C
Figure 2 Morphology of the kidneys of Snell dwarf mice after different administration regimen. (A) PBS control: overview of the cortical
and medullary area. (B) PBS control: cortex. (C) PBS control: outer medulla. (D) IGF-I administration: outer medulla. (E) IGFBP-1
administration: outer medulla. (F) IGFBP-1+ IGF-I administration: outer medulla. Black arrows: dilatations of the thin limbs of Henle’s loop.
Abbreviations: C=cortex, IC= inner cortex, DT=distal tubule, G=glomerulus, m=mesangial cells, OM=outer medulla, pc=peritubular
capillary, PT=proximal tubule, tl=thin limb of Henle’s loop, TL=thick limb of Henle’s loop. Bar=25 m.
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shows the morphology of the dwarf mouse kidney. After
treatment with IGFBP-1 (Fig. 2E) and IGFBP-1+IGF-I
(Fig. 2F), kidneys of Snell dwarf mice demonstrated
pronounced dilatation of thin limbs of Henle’s loop in the
medulla. This dilatation could not be observed in IGF-I
(Fig. 2D) and hGH (results not shown) treated mice.
Regardless of the treatment, kidney weight increased
simultaneously with kidney size. To determine if
increased kidney weight reflected an increase in cell
number, nuclei were counted in cortical areas. Kidney
length and kidney weight were plotted against the number
of cell nuclei per cortical area (Fig. 3). In glomeruli, no
changes in numbers of nuclei between the different
treatment regimen were observed (data not shown). In the
tubular cortical region and compared with control, a
decreased number of nuclei per cortical area was found for
all treatments, except for IGF-I. After treatment of IGF-I,
kidney length and weight were increased, while the cell
number per area did not change. In contrast, treatment of
Snell dwarf mice with hGH, IGFBP-1 or IGF-I+
IGFBP-1 caused an increase in kidney length and weight,
while the cell number per cortical area decreased simul-
taneously (Fig. 3). Also, staining against the cell prolifer-
ation marker PCNA revealed an increased cell labeling
Figure 4 Analysis of type 1 IGF receptor mRNA (blue), and type 1 IGF receptor, IGFBP-3 and -4 protein (brown) in kidneys of Snell dwarf
mice injected for 28 days with PBS (control) (A, E, I, K); GH (B, F); IGFBP-1 (C, G, J, L); and IGF-I+IGFBP-1 (D, H). (A) Type 1 IGF receptor
mRNA of the control group in the cortical region in proximal tubules, thick limbs of Henle’s loop, distal tubules and glomeruli. (B) Type 1
IGF receptor mRNA in the GH group in the cortical region in proximal tubules, thick limbs of Henle’s loop, distal tubules and glomeruli.
(C) Type 1 IGF receptor mRNA in the IGFBP-1 group in the cortical region in proximal tubules, thick limbs of Henle’s loop, distal tubules
and glomeruli. (D) Type 1 IGF receptor mRNA in the IGFBP-1+IGF-I group in the cortical region in proximal tubules and thick limbs of
Henle’s loop. (E) Type 1 IGF receptor protein in the control group in the cortical region in proximal tubules, distal tubules and thick limbs
of Henle’s loop. (F) Type 1 IGF receptor protein in the GH group in the cortical region in proximal tubules, distal tubules and thick limbs
of Henle’s loop. (G) Type 1 IGF receptor protein in the IGFBP-1 group in the inner cortical region in proximal tubules and thick limbs of
Henle’s loop. (H) Type 1 IGF receptor protein in the IGFBP-1+IGF-I group in the inner cortical region in proximal tubules and thick limbs
of Henle’s loop. (I) IGFBP-3 protein in the control group in the inner cortical region in peritubular capillaries. (J) IGFBP-3 protein in the
IGFBP-1 group in the inner cortical region in peritubular capillaries. (K) IGFBP-4 protein in the control group in the cortical region in
proximal tubules and in thick and thin limbs of Henle’s loop. (L) IGFBP-4 protein in the IGFBP-1 group in the cortical region in proximal
tubules. BP1= IGFBP-1, BP-3= IGFBP-3, BP-4= IGFBP-4, DT=distal tubule, G=glomerulus, pc=peritubular capillary, PT=proximal tubule,
t1rec=type 1 IGF receptor, tl=thin limb of Henle’s loop, TL=thick limb of Henle’s loop. Bar=25 m.
Figure 3 Mean kidney length (per kidney) and weight (per pair of kidneys)S.E.M. were plotted against the
mean number of nucleiS.E.M. per cortical area, for all treatments. *Significant difference with P=0·05.
 PBS;  GH; ♦ IGF-I;  IGFBP-1;  IGF-I+ IGFBP-1.
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index in the IGF-I treatment group only (results not
shown).
Renal expression of the members of the IGF system
mRNA localization Table 1A shows the renal mRNA
expression patterns of the members of the IGF system of
the control mice. These were similar to those described
previously for kidneys obtained from normal BALB/c
mice (Lindenbergh-Kortleve et al. 1997). mIGFBP-1 and
mIGFBP-6 mRNA expression was very weak in kidneys
of all administration groups and no differences were
observed between the various administration modalities
(results not shown). In Figs 4 and 5, representative mRNA
expression patterns for the type I IGF-receptor, the IGFs
and the IGFBPs of kidneys from GH, IGF-I, IGFBP-1
and IGFBP-1+IGF-I administered mice are shown, in
order to illustrate the data used for Table 1B where
differences, as compared with controls, are given, based on
the screening of five animals for each treatment.
Control In kidneys of heterozygous normal and
homozygous dwarf control mice, type I IGF receptor
mRNA was localized in Bowman’s capsule, distal and
proximal tubules and thick limbs of Henle’s loop (Fig. 4A).
IGF-I mRNA was located in Bowman’s capsule, proximal
and distal tubules, peritubular capillaries of the inner
cortex and the medulla and thick limbs of Henle’s loop
(Fig. 5A). Localization of IGF-II mRNA was found in
Bowman’s capsule, distal and proximal tubules and thick
limbs of Henle’s loop (Fig. 5B). IGFBP-2 mRNA was
observed in the cortex in Bowman’s capsule, thick limbs of
Henle’s loop, distal tubules and to a lesser extent in
proximal tubules (Fig. 5C). In the medulla, IGFBP-2
hybridization signals were found in the thick and thin
limbs of Henle’s loop (results not shown). Localization of
IGFBP-3 mRNA was confined to peritubular capillaries
of the outer cortex and the medulla (results not shown).
Hybridization signals for IGFBP-4 mRNA were found in
mesangial cells of glomeruli, proximal tubules, cortical
thick limbs of Henle’s loop and in peritubular capillaries of
both the cortex and outer medulla (results not shown).
IGFBP-5 mRNA was localized in the cortex in mesangial
cells of glomeruli, juxtaglomerular cells, distal tubules and
in peritubular capillaries of the outer cortex and medulla
(Fig. 5G).
GH administration In GH-administered dwarf mice,
renal expression of the type I IGF-receptor mRNA was
increased in distal tubules (Fig. 4B). Also IGFBP-2
mRNA expression was increased in the inner cortex in
distal tubules (results not shown).
IGF-I administration IGF-system mRNA expression
in kidneys of IGF-I administered dwarf mice was largely
comparable to kidneys from control animals (results not
shown). Only IGFBP-2 mRNA expression was more
pronounced in distal tubules and cortical thick limbs of
Henle’s loop (results not shown).
IGFBP-1 administration IGFBP-1 administration
revealed important changes in renal IGF-system mRNA
expression. Type I IGF receptor mRNA expression was
increased in the cortex in proximal tubules and in the
thick limbs of Henle’s loop (Fig. 4C). IGF-I mRNA
expression was increased in the thick limbs of Henle’s loop
Table 1 (A) mRNA localization in control group (PBS). (B) Changes in mRNA expression after different administration regimen
t1rec IGF-I IGF-II BP-2 BP-3 BP-4 BP-5
(A) mRNA localization
Structures
Cortex
Glomeruli: Mesangial cells + +
Bowman’s capsule + + + +
Proximal tubules + + + + +
Thick limbs of Henle’s loop + + + + +
Distal/collecting tubules + + + + +
Peritubular capillaries + + + +
Medulla
Thick limbs of Henle’s loop/collecting ducts + + + +
Thin limbs of Henle’s loop +
Peritubular capillaries + + + +
(B) Changes in mRNA expression
Administration
GH 	 	
IGF-I 	
IGFBP-1 	 	 	 	 	
IGFBP-1/IGF-I 	 	
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in both cortex and medulla (Fig. 5D). Similarly, staining of
IGF-II mRNA was enhanced in cortical thick limbs of
Henle’s loop (Fig. 5E). Increased IGFBP-2 mRNA signal
was found in distal tubules of the cortex (results not
shown). Furthermore, the number of epithelial cells
from distal tubules that demonstrated IGFBP-5 mRNA
expression was increased after IGFBP-1 treatment
(Fig. 5J).
IGFBP-1+IGF-I administration Combined admin-
istration of IGFBP-1+IGF-I demonstrated elevated type I
IGF receptor mRNA signals in the thick limbs of Henle’s
loop (Fig. 4D). IGFBP-2 mRNA expression was elevated
in Bowman’s capsule and in distal tubules (Fig. 5F).
Protein localization
Results of immunohistochemistry of kidneys of the differ-
ent groups are summarized in Table 2A. Representative
expression patterns for the type I IGF-receptor and the
IGFBPs (Figs 4 and 5) of kidneys from GH, IGF-I,
IGFBP-1 and IGFBP-1+IGF-I administered mice are
shown, in order to illustrate the data used for Table 2B
where differences, as compared with controls, are given
based on the screening of five animals for each treatment.
IGF-I, -II, IGFBP-1 and -6 could not be detected
immunohistochemically.
Control The kidneys of control dwarf mice revealed type
I IGF receptor protein localization in proximal tubules,
distal tubules and in thick limbs of Henle’s loop in cortex
and medulla (Fig. 4E). IGFBP-2 protein was detected in
proximal tubules and thick and thin limbs of Henle’s loop
(Fig. 5I). IGFBP-3 protein was localized in peritubular
capillaries of both the cortex (Fig. 4I) and the outer
medulla. IGFBP-4 localization was demonstrated in
mesangial cells in the glomeruli, in proximal tubules and in
thick and thin limbs of Henle’s loop (Fig. 4K). IGFBP-5
staining was weak and could be confined to proximal
tubules (Fig. 5H).
GH administration When comparing the GH infused
group with the control group, renal type I IGF receptor
staining was more intense in proximal tubules and cortical
thick limbs of Henle’s loop (Fig. 4F). All other members of
the IGF system showed identical staining patterns as in
kidneys of control animals (Table 2).
IGF-I administration Compared with controls, IGF-I
administration did not result in any difference in staining
patterns for the IGF system members that were tested as is
illustrated for type I IGF receptor (results not shown).
IGFBP-1 administration Type I IGF receptor protein
staining was decreased in proximal and distal tubules and
in thick limbs of Henle’s loop (Fig. 4G). Compared with
the control group, IGFBP-3 staining was decreased in
peritubular capillaries in both cortex and medulla (Fig. 4J).
IGFBP-4 staining was increased in the brush border of
proximal tubules (Fig. 4L). IGFBP-5 showed a more
intense staining in distal tubules (Fig. 5K).
IGFBP-1+IGF-I administration The staining patterns
of the IGF system components after combined IGFBP-1+
IGF-I treatment largely resembled the patterns found
after IGFBP-1 treatment, except for IGFBP-2 that was
decreased in proximal tubules and the thick limbs of
Henle’s loop (Fig. 5L). Comparable to the IGFBP-1
administered group, type I IGF receptor protein staining
was strongly decreased in proximal and distal tubules and
in thick limbs of Henle’s loop (Fig. 4H). IGFBP-3 staining
was decreased in peritubular capillaries in both cortex and
medulla, IGFBP-4 staining was increased in the brush
border of proximal tubules and IGFBP-5 showed a more
intense staining in proximal and distal tubules (results not
shown).
Discussion
In our previous study we have demonstrated that treat-
ment of homozygous Snell dwarf mice with GH and
IGF-I, for a period of 4 weeks, caused an increase in body
length and body weight (van Buul-Offers et al. 2000).
GH, IGF-I and IGFBP-1 treatment also had a pronounced
effect on kidney size. Although IGFBP-1 inhibited IGF-I
induced total body growth, it further stimulated IGF-I
induced kidney growth (van Buul-Offers et al. 2000). In
this study we investigated the renotropic effects of
IGFBP-1 in further detail.
Effects of GH, IGF-I and/or IGFBP-1 on kidney
morphology
In the present study the effects of GH, IGF-I, IGFBP-1
and IGFBP-1+IGF-I administration on the morphology
and the expression pattern of members of the IGF system
in kidneys of Snell dwarf mice were analyzed. Although an
increased wet weight of the kidneys was observed in all
treatment groups, when compared with controls, the
morphology was different. When IGFBP-1, alone or in
combination with IGF-I, was administered, fluid filled
dilatations of thin limbs of Henle’s loop were observed.
This increased kidney weight occurred with a decreased
mean number of nuclei per cortical area. Thus, we may
conclude that short-term IGFBP-1 or IGF-I+IGFBP-1
treatment affected renal intracellular fluid accumu-
lation and not cellular proliferation, as supported by an
unchanged proliferation labeling index. This in contrast
with treatment with IGF-I alone resulting in enlarged
kidney size, due to enhanced kidney cell growth.
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This study is comparable with a previous study by van
Buul-Offers and co-workers (1995), where the effects of
IGFBP-3 and IGF-I, alone and in combination, were
investigated on total body and organ growth. In contrast to
IGFBP-1, IGFBP-3 inhibited IGF-I induced kidney
growth, whereas administration of IGFBP-3 alone did not
affect kidney size. In retrospect, we also observed no
differences in morphology of the IGFBP-3 treated kidneys
compared with the controls (data not shown). These
findings might indicate different functions for IGFBP-1
and IGFBP-3 in the kidney.
The renal effects of IGFBP-1 administration in our
present study seemed to be in contrast with observations in
transgenic mouse models that overexpress IGFBP-1. In
transgenic animals overexpressing IGFBP-1 under control
of the metallothionein or phosphoglycerate promoter, no
gross changes in kidney size and morphology were de-
scribed (Dai et al. 1994, Murphy et al. 1995). It must be
mentioned that in these transgenic animals elevated cir-
culatory IGFBP-1 levels were not observed. In contrast,
transgenic animals overexpressing IGFBP-1 under control
of the liver-specific 1-antitrypsin promoter demonstrated
a marked increase in the mesangial extracellular matrix.
However, the total glomerular volume was not increased,
suggesting that these IGFBP-1 transgenic animals devel-
oped glomerulosclerosis without glomerular hypertrophy
(Doublier et al. 2000).
In the present study, administration of GH or IGF-I to
the Snell dwarf mice resulted in enlarged kidneys, con-
firming previous reports (Hirschberg 1993, van Buul-
Offers et al. 1995). Overexpression of GH and/or IGF-I in
transgenic mice affected renal morphology (Quaife et al.
1989, Wanke et al. 1991). This, however, differed from
the observations in our study. Kidneys of GH transgenic
mice showed glomerulosclerosis and tubular cysts (Brem
et al. 1989) whereas in our study no effects on kidney
Table 2 (A) Protein localization in control group (PBS). (B) Changes in protein expression
after different administration regimen
t1rec BP-2 BP-3 BP-4 BP-5
(A) Protein localization
Structures
Cortex
Glomeruli: Mesangial cells +
Bowman’s capsule
Proximal tubules + + + +
Thick limbs of Henle’s loop + + +
Distal/collecting tubules + +
Peritubular capillaries +
Medulla
Thick limbs of Henle’s loop/collecting ducts + + +
Thin limbs of Henle’s loop + +
Peritubular capillaries +
(B) Changes in protein expression
Administration
GH 	
IGF-I
IGFBP-1 
 
 	 	(d)
IGFBP-1/IGF-I 
 
 
 	 	
(d) in distal/collecting tubules.
Figure 5 Analysis of IGF-I, -II, IGFBP-2 and -5 mRNA (blue) and protein (brown) in kidneys of Snell dwarf mice injected for 28 days with
PBS (control) (A–C, G–I); IGFBP-1 (D, E, J, K); and IGF-I+IGFBP-1 (F, L). (A) IGF-I mRNA in the control group in the inner cortical region in
peritubular capillaries, thick limbs of Henle’s loop, and proximal tubules. (B) IGF-II mRNA in the control group in the inner cortical region
in proximal tubules and thick limbs of Henle’s loop. (C) IGFBP-2 mRNA in the control group in the outer cortical region in Bowman’s
capsule, distal tubules, and proximal tubules. (D) IGF-I mRNA in the IGFBP-1 group in the cortical region in proximal tubules and thick
limbs of Henle’s loop. (E) IGF-II mRNA in the IGFBP-1 group in the inner cortical region in proximal tubules and in the thick limbs of
Henle’s loop. (F) IGFBP-2 mRNA in the IGFBP-1+IGF-I group in the outer cortical region in distal tubules and Bowman’s capsule.
(G) IGFBP-5 mRNA in the control group in the cortical region in mesangial cells, peritubular capillaries, and distal tubules. (H) IGFBP-5 in
the control group in the cortical region in proximal tubules. (I) IGFBP-2 in the control group in the cortical region in proximal tubules, thick
and thin limbs of Henle’s loop. (J) IGFBP-5 mRNA in the IGFBP-1 group in the cortical region in distal tubules. (K) IGFBP-5 in the IGFBP-1
group in the cortical region in proximal and distal tubules. (L) IGFBP-2 in the IGFBP-1+IGF-I group in the cortical region in proximal
tubules and thick limbs of Henle’s loop. BC=Bowman’s capsule, BP1= IGFBP-1, BP-2= IGFBP-2, BP-5= IGFBP-5, DT=distal tubule,
m=mesangial cells, pc=peritubular capillary, PT=proximal tubule, tl=thin limb of Henle’s loop, TL=thick limb of Henle’s loop. Bar=25 m.
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morphology were seen. These differences might be
explained by the fact that in the transgenic animals,
circulating levels of GH were pharmacologically high
whereas in our (dwarf) model we used substitution doses
(Brem et al. 1989). Supranormal levels of IGF-I in
transgenic animals resulted in enlarged glomeruli (Quaife
et al. 1989). The circulating IGF-I levels of these trans-
genic mice and of the IGF-I-treated dwarf mice in our
study were comparable (540 and 417 µg/l respectively)
(Mathews et al. 1988, van Buul-Offers et al. 2000),
although the transgenic animals have constant circulatory
IGF-I levels whereas in our study IGF-I was administered
three times per day, for 4 weeks. Interestingly, also in our
study, a tendency towards an increase in glomerular
volume was observed.
We only can speculate about the mechanisms of the
tubular effects of IGFBP-1, which is solely observed in
groups that received IGFBP-1, either alone or in combi-
nation with IGF-I and is not seen in the IGF-I admin-
istration group. It can be hypothesized that, under normal
circumstances, circulatory IGF-I, when it is predomi-
nantly bound to IGFBP-3, does not leave the glomerular
capillary network. In contrast, when IGFBP-1 is present
abundantly, IGFBP-1/IGF-I complexes will be formed
and transported from the glomerular capillary network
into the tubular system. Here, IGFBP-1 determines the
tubular bioavailability for the IGFs. This hypothesis is
favored by a body of experimental evidence. First, the
renal morphological effects of prolonged IGF-I over-
expression in transgenic animals only are limited to
glomerular hypertrophy (Doi et al. 1990). In addition,
IGF-I administration, both in the human and in exper-
imental animals, had direct effects on glomeruli where it
increased renal plasma flow and glomerular filtration rate
with a concomitantly decreased vascular resistance (Feld
& Hirschberg 1996a). Furthermore, in hypokalemia,
increased renal IGFBP-1 mRNA and increased immuno-
reactive IGFBP-1 has been observed, which is spatially
associated with tubular hyperplasia (Hsu et al. 1997,
Rohan et al. 1997, van Neck et al. 1997). These results
suggest that IGFBP-1/IGF-I might play a major role in
distal nephron adaptation.
Whether the effects of IGFBP-1 are IGF-I dependent
or independent needs to be further elucidated. In this
respect, a role for IGFBP-1 has been suggested in a
streptozotocin induced diabetes model (Landau et al. 1995,
Feld & Hirschberg 1996b, Raz et al. 1998, Segev et al.
1999). Feld & Hirschberg (1996b) suggested that
IGFBP-1 may have a stimulating effect on kidney growth,
independent of IGF-I, through mitogenic actions via
52-integrins. Our results indicate, however, that these
putative IGF-independent functions of IGFBP-1 were not
blocked when IGF-I was co-administered with IGFBP-1,
suggesting that IGF-I binding to its own receptor does not
interfere with the putative IGF-independent actions of
IGFBP-1.
Effects on renal expression of IGF system components
Of all administration regimen, the effect of IGFBP-1
administration on expression patterns of IGF system
mRNA and protein was most prominent. Furthermore,
the administered compounds had different effects on
mRNA expression and protein localization. Most remark-
able was the finding that the effects of administration of
IGFBP-1 or IGFBP-1+IGF-I had similar effect on IGF
system protein levels. Also the morphological changes after
IGFBP-1 or IGFBP-1+IGF-I administration were identi-
cal. These findings, again, might indicate that IGFBP-1
plays an important role in the kidney.
Our results show a considerable overlap in the localiz-
ation of the IGF system mRNA and protein. However,
compared with protein, a larger number of different
members of the IGF system were detected at the mRNA
level. Furthermore, mRNA expression in a given cell type
was not necessarily followed by the detectable presence of
the corresponding protein in that cell type. It is unclear
whether these differences represent a protein expression
below the detection limit of our immunohistochemical
assay, or whether these reflect the nature of these proteins.
After all, the IGFs and IGFBPs are secreted proteins. Thus,
mRNA levels and localization may deviate from protein
levels and localization. Therefore, protein patterns
likely are more informative when trying to elucidate the
function(s) of the IGFBPs.
Discrepancies between mRNA and protein of IGF
system components in the kidney have been reported in
several studies. For example, in normal rat tubules, hardly
any IGF-I mRNA is detected (Matejka & Jennische 1992,
Matejka et al. 1992), while the protein is clearly found in
proximal tubules (Kobayashi et al. 1991). This suggests that
the majority of IGF-I protein in the kidney might
be trapped from the circulation (D’Ercole et al. 1984,
Mathews et al. 1986, Feld & Hirschberg 1996b). In our
study, IGF-I protein could not convincingly be detected in
any of the groups. This might be due to the specificity of
the rabbit anti-human polyclonal antiserum in mouse
immunohistochemistry.
A complicating factor in matching our findings with the
literature is that descriptions of changed IGF system
expression patterns in renal disease models are scarce and,
if existing, are often derived from rat studies where,
compared with mice, differences in IGF system expression
are observed, especially regarding IGFBP-1 expression
(Chin et al. 1992, Price et al. 1995, Rabkin et al. 1995,
Lindenbergh-Kortleve et al. 1997).
In our study, the effects of GH or IGF-I administration
on kidney morphology and changes in IGF system expres-
sion seemed to be comparable, and less prominent than the
effects of IGFBP-1 or IGFBP-1+IGF-I administration.
When we examine the similarities in IGF system
protein patterns between the IGFBP-1 and the IGFBP-1+
IGF-I group, both demonstrate increased IGFBP-4 levels
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in the thick limbs of Henle’s loop. These may play an
important role in the onset of fluid accumulation and/or
formation of dilatated thin limbs of Henle’s loop. Further-
more, IGFBP-5 levels in the proximal tubules were found
to be increased whereas IGFBP-3 levels in the peritubular
capillaries and type I IGF receptor levels in the distal/
collecting tubules were decreased. However, we can not
exclude that the changes in IGF system protein expression
are not sufficient to induce the observed fluid accumu-
lation and/or dilatation of the thin limbs of Henle’s
loop. Therefore, we suggest that a complex network of
interacting factors may be implicated in this process.
In summary, we have shown that treatment with
IGFBP-1 and IGFBP-1+IGF-I of Snell dwarf mice causes
specific morphological changes in the kidney. Further-
more, specific alterations on mRNA as well as on protein
levels of the IGF system occur. We suggest that IGFBP-1,
directly or by regulating IGF bioavailability, may affect
renal fluid exchange and/or increase hydrostatic pressure
that may cause dilatations of the thin limbs of Henle’s loop.
Hence, our study provides a framework for a further
understanding of the role of IGFBP-1 in renal physiology.
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